POLYMED Poly Medicure Q4 FY25 results (Jan–Mar 2025) and concall
Poly Medicure delivered a strong set of Q4 and FY25 numbers, meeting its previous guidance on both revenue and margins. The company is successfully pivoting towards high-growth verticals like Renal and Cardiology while maintaining a dominant position in Vascular Access. Despite geopolitical headwinds affecting export guidance (12-15%), the management remains highly optimistic about the domestic market and is aggressively expanding capacity and R&D headcount to support future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 420 | 424 | 441 |
| EBITDA | 115 | 114 | 119 |
| Net profit | 87 | 85 | 92 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
